Century Therapeutics, Inc.
IPSC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850119
In the last 90 days, Century Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 100 institutions reported holding it in 13F filings for Q2 2026, worth $387.0M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $304.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $10.2K in total
- 5
- 13F holdersQ2 2026, +28 vs. previous quarter
- 100
- 13F valueReported value at the end of Q2 2026
- $387.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $109.2M
- +1,556.8% year over year
- Net income, FY2025
- -$9.58M
- No comparable prior period
- Free cash flow, FY2025
- -$104.7M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $9.58M (8.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 32.0M
- Shares sold short
- Change
- +2.89M
- +9.9% vs. previous
- Days to cover
- 30.96
- At average daily volume
Superinvestors holding IPSC, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding IPSC at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Century Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)4:10 PM ET | Nov 3 | 2 days | Carr DouglasSVP Finance & Operations | SSale | −266 | $1.52 | −$404.05 | −0.1%502.6K after | |
| Sep 15, 2026 (view filing)6:25 PM ET | Sep 14 | 1 day | Russotti GregorySee Remarks | SSale | −2.59K | $1.93 | −$4.99K | −0.5%509.2K after | |
| Sep 15, 2026 (view filing)6:25 PM ET | Sep 14 | 1 day | Carr DouglasSVP Finance & Operations | SSale | −1.66K | $1.93 | −$3.20K | −0.3%502.9K after | |
| Sep 9, 2026 (view filing)4:35 PM ET | Sep 8 | 1 day | Russotti GregorySee Remarks | SSale | −534 | $2.05 | −$1.09K | −0.1%511.8K after | |
| Sep 9, 2026 (view filing)4:34 PM ET | Sep 8 | 1 day | Carr DouglasSVP Finance & Operations | SSale | −254 | $2.05 | −$520.7 | −0.1%504.6K after | |
| Aug 5, 2026 (view filing)4:08 PM ET | Aug 3 | 2 days | Carr DouglasSVP Finance & Operations | SSale | −275 | $1.98 | −$543.68 | −0.1%504.8K after | |
| Jun 15, 2026 (view filing) | Jun 12 | 3 days | Russotti GregorySee Remarks | SSale | −2.58K | $2.23 | −$5.76K | −0.5%512.3K after | |
| Jun 15, 2026 (view filing) | Jun 12 | 3 days | Carr DouglasSVP Finance & Operations | SSale | −1.65K | $2.23 | −$3.69K | −0.3%505.1K after | |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Russotti GregorySee Remarks | SSale | −524 | $2.11 | −$1.11K | −0.1%514.9K after | |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Carr DouglasSVP Finance & Operations | SSale | −249 | $2.11 | −$525.39 | 0.0%506.7K after |
Top 10 13F holders, Q2 2026
See all 100 holdersThe largest institutional positions in Century Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 17,754,430 | $43.5M | 0.38% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 17,754,430 | $43.4M | 1.04% | 00.0% | Unchanged |
| Versant Venture Management, LLC | 12,166,109 | $29.8M | 18.33% | 00.0% | Unchanged |
| Deep Track Capital, LP | 9,462,645 | $23.2M | 0.34% | −25,100−0.3% | Reduced |
| RTW Investments, LP | 8,695,652 | $21.3M | 0.18% | 00.0% | Unchanged |
| VR Adviser, LLC | 8,695,652 | $21.3M | 0.65% | 00.0% | Unchanged |
| Commodore Capital LP | 8,695,652 | $21.3M | 1.27% | 00.0% | Unchanged |
| BlackRock, Inc. | 8,091,768 | $19.8M | 0.00% | +6,567,346+430.8% | Added |
| Vanguard Capital Management LLC | 5,703,680 | $14.0M | 0.00% | +17,476+0.3% | Added |
| Balyasny Asset Management LLC | 5,522,944 | $13.5M | 0.02% | +505,211+10.1% | Added |
Holders of 5% or more of IPSC
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Century Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13G | 9.90%17.9M shares | New | Jan 16, 20261 filing | Jan 16, 2026 | SEC |
| TCG Crossover GP II, LLC | 13G | 9.90%17.8M shares | New | Jan 15, 20261 filing | Jan 15, 2026 | SEC |
| Deep Track Capital, LP | 13G | 7.34%13.5M shares | New | Jan 15, 20261 filing | Jan 15, 2026 | SEC |
| RTW Investments, LP | 13G | 7.10%13.0M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G | 7.10%13.0M shares | +2.40 ppfrom 4.70% | Mar 4, 20244 filings | Jan 16, 2026 | SEC |